Navigation Links
Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin(R) (MP-376) Treatment in Cystic Fibrosis Patients
Date:9/10/2009

bulizer System, an inhalation delivery device optimized specifically for Aeroquin. The Investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of medication via a vibrating, perforated membrane that includes thousands of small holes to produce the aerosol mist. Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time. Combined with its quiet mode of operation, small size (it fits in the palm of the patient's hand), light weight and battery use, eFlow Technology reduces the burden of taking daily, inhaled treatments. PARI Pharma focuses on the development of aerosol delivery devices and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together.


'/>"/>
SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane-disrupting Agent, EP-100, in Patients with Cancer
2. Rib-X Pharmaceuticals to Present at the 49th ICAAC
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
5. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet
8. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
9. Alexza Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
11. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 Three ... be semi-finalists in Livestrong’s Big C Competition. Out of ... are each headed to the semi-final round. In this ... exclusive three-month accelerator program, complete with mentoring from thought-leaders ... , As part of the angelMD commitment to the ...
(Date:7/24/2014)... July 24, 2014  Neogen Corporation (Nasdaq: ... of its potential revenue from new rodenticide research are ... and analysts on July 22, 2014, Neogen,s CEO commented ... this research. "It was my intent Tuesday ... potential of a new type of rodenticide, but certainly ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... ... Prize in Chemistry published papers on their award-winning work based on data collected at the ... ... Nobel Prize in Chemistry published papers on their award-winning work based on data collected at ...
... Inc. (Nasdaq: LXRX ) today announced that it ... conditions, 27,500,000 shares of its common stock pursuant to ... are being offered through the underwriters and 11,087,387 shares ... Lexicon also intends to grant the underwriters a ...
... ... President Obama , ... Argonne, Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient ... President Barack Obama as a Medal of Technology and Innovation award-winner on October 7 ...
Cached Biology Technology:Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 2Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 3Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... 24, 2014) Scientists at The New York ... step closer to creating a viable cell replacement ... cells. , For the first time, NYSCF ... from skin samples of patients with primary progressive ... protocol to induce these stem cells into becoming ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Creating sustainable STEM teacher preparation programs 2
... Mich. --- Scientists have discovered a molecular process in ... a target for treatments to prevent or reverse addiction ... of Neuroscience , Michigan State University neuroscientist A.J. Robison ... brain,s pleasure center that responds to stimuli such as ...
... can literally be the difference between life and death. ... stood out starkly against the light-colored, sandy soil, making them ... the mice evolved a new system of camouflage lighter ... in the extent of pigment across their body that ...
... Pilot whales that have died in mass strandings ... at each event, a new study concludes, challenging a ... beach and to almost certain death because of familial ... strandings, scientists have determined that both related and unrelated ...
Cached Biology News:Discovery could yield treatment for cocaine addicts 2One gene, many mutations 2One gene, many mutations 3Study questions the role of kinship in mass strandings of pilot whales 2Study questions the role of kinship in mass strandings of pilot whales 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Rabbit Polyclonal antibody to Perilipin Applications: This antibody is useful for Western blot anlaysis where a band at ~60 kDa is seen....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... designer enzyme that enables RT-PCR in ... enzyme allows reverse transcription and PCR ... temperatures (65C), which helps to remove ... results in highly stringent, accurate annealing ...
Biology Products: